Is Ayala Pharmaceuticals Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Ayala Pharmaceuticals Inc (ADXS) is currently classified as NOT HALAL as of May 2024. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Ayala Pharmaceuticals Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Ayala Pharmaceuticals Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Ayala Pharmaceuticals Inc?

Muslim investors may consider investing in Ayala Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Ayala Pharmaceuticals Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Ayala Pharmaceuticals Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Ayala Pharmaceuticals Inc updated?

The Shariah compliance status of Ayala Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Ayala Pharmaceuticals Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Ayala Pharmaceuticals Inc?

You can check the latest Shariah compliance status of Ayala Pharmaceuticals Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ADXS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 21, 2024

Report Source: 2023 Annual Report

Ayala Pharmaceuticals Inc. Stock Analysis ADXS

United States Health Care Nano Cap Report: 2023 Annual

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. The company is headquartered in Monmouth Junction, New Jersey and currently employs 20 full-time employees. The company went IPO on 2005-07-28. The firm's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.

Key Statistics of Ayala Pharmaceuticals Inc (ADXS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.60$0.62

Today's Open

$0.60

Volume

13.59K

P/E Ratio (TTM)

52 Week Range

$0.00$0.80

Market Cap

24.30M

Avg. Volume